The rational treatment of metastatic NSCLC hinges on the timely detection of potentially targetable genomic alterations to guide therapy. Recent advances in highly sensitive genotyping technologies have allowed for development of novel plasma genotyping assays that are capable of noninvasively detecting targetable alterations in plasma cell-free DNA without reliance on traditional tissue genotyping.
Introduction
Plasma genotyping is a novel diagnostic tool that has rapidly entered clinical use in thoracic oncology. This technology studies cell-free DNA (cfDNA) present in the plasma, a portion of which can be tumor derived, to perform noninvasive tumor genotyping. The appeal of this technology is particularly evident in advanced NSCLC, in which treatment decisions depend on the timely detection of genomic alterations conferring sensitivity or resistance to specific targeted therapies. Plasma genotyping affords oncologists the ability to rapidly obtain information on tumor genotype while avoiding the inherent risk and discomfort associated with tissue biopsy.
A seemingly endless array of platforms has been utilized to study cfDNA and develop plasma genotyping assays. Each of these platforms and the associated plasma genotyping assays possesses unique test characteristics and potential limitations. The proper clinical use of a given assay can be informed only by careful validation against a reference standard such as tissue genotyping. The multitude of available assays and the variability in the rigorousness of the validation of each has led to confusion as to how to best utilize this new technology for clinical care in lung cancer. The effective use of this promising new technology by clinicians hinges on a shrewd understanding of the test characteristics and validation of a given assay, recognition of the differences between assays, identification of patients in whom plasma genotyping is useful, and understanding of how to interpret the results of these assays at different points in a given patient's treatment course. Here we will explore key questions surrounding the technology of plasma genotyping, the available assays, and the clinical use of this technology.
What Are the Biological Underpinnings of Plasma Genotyping?
The existence of double-stranded cfDNA fragments in the plasma as a by-product of cell death was first demonstrated decades ago. 1 The observation that levels of cfDNA were higher in patients with cancer than in patients without cancer led to the subsequent experiments establishing that a small fraction of cfDNA is tumor derived. [2] [3] [4] The relatively low level of such tumor-derived cfDNA in plasma has meant that the detection of targetable genomic alterations to direct therapy in lung cancer has historically depended on genotyping tumor biopsy specimens. However, the development of increasingly sensitive genotyping methods for tissue analysis has recently allowed the reliable detection of targetable genomic alterations present in the fraction of plasma cfDNA derived from tumor cells. The minor fraction of tumor-derived cfDNA present in patient plasma can be analyzed by using these highly sensitive plasma genotyping platforms to identify potentially targetable genomic alterations present in a patient's tumor. However, the detection of mutant tumor cfDNA in patient plasma depends on the release of tumor DNA into the circulation-a phenomenon best described as cfDNA "shed."
The concept of cfDNA shed is central to the development and interpretation of plasma genotyping assays. The rate at which tumor cells release DNA into the circulation relative to the rate at which it is eliminated by renal clearance determines the concentration of tumor-derived cfDNA present in the plasma and thus is the primary predictor of the sensitivity of any plasma genotyping assay. The process of tumor cfDNA shed is incompletely understood but theorized to be related to aspects of tumor biology, including mitotic rate, necrosis, and vascularization multiplied by the total number of tumor cells present. 5, 6 The overall burden of metastatic disease in a patient and the presence of metastatic disease in the liver and bone have previously been demonstrated to predict for increased plasma genotyping sensitivity and thus tumor cfDNA shed. 7, 8 The ability of any plasma genotyping assay to detect a given mutation in a tumor is thus directly related to the degree of tumor cfDNA shed as even the most sensitive genotyping assay can detect only what is released into the peripheral circulation (Fig. 1) .
The concept of tumor heterogeneity is also important in the interpretation of plasma genotyping assays, which are compared against tissue genotyping as the reference standard in most validated assays to date. Studies that have compared mutational profiles of different sites of metastatic disease from the same patient have established the intratumoral heterogeneity and spatial and temporal tumor heterogeneity of solid tumors. 9, 10 Thus, a single tumor biopsy at one time point may not represent the complex genetic profile of a patient's tumor and introduces the chance of false-negative results. Plasma genotyping assesses cfDNA that is shed into the periphery from multiple sites of disease and thus may be a more accurate means of capturing the genetic heterogeneity of a tumor. The interpretation of mutations that are captured on plasma genotyping and not tissue genotyping is discussed in later sections of this review article.
What Are the Key Differences between Different Plasma Genotyping Platforms?
The detection of genomic alterations of interest in plasma cfDNA requires, first, careful isolation of plasma cfDNA to limit contamination with genomic DNA and, second, use of a highly sensitive genotyping assay. Isolation of cfDNA by methods designed to collect plasma in a fashion that minimizes cell disruption and thus contamination with leukocyte-derived DNA is essential to optimizing assay performance. The use of serum or slow sample processing has been demonstrated to increase such contamination. 11 A multitude of semiquantitative and quantitative genotyping platforms have been utilized for the purpose of plasma genotyping. However, the individual test characteristics of a given plasma genotyping assay hinge on the underlying genotyping platform and can be variable. Furthermore, important differences exist between these various platforms with respect to the number of genomic alterations included in a single panel, the ability to multiplex these assays, the turnaround time of the test, and its ability to detect complex genomic alterations such as rearrangements and copy number alterations.
The earliest studies of plasma genotyping of cfDNA in lung cancer utilized direct sequencing and the scorpionamplified refractory mutation system (scorpion-ARMS) technology to detect both EGFR exon 19 deletion (del) and L858R mutations in both the serum and tumor tissue of patients with metastatic lung cancer before treatment with gefitinib. 12, 13 These studies were the first in NSCLC to demonstrate that a targetable genomic alteration could be detected in the blood of patients with metastases. Kimura et al. utilized this platform in a cohort of 42 patients receiving gefitinib monotherapy and demonstrated a sensitivity of 85.7% and specificity of 94.3% for the detection of EGFR-mutant cfDNA. 12 Multiple subsequent retrospective studies have further elucidated the test characteristics of scorpion-ARMSbased genotyping, which allows for the semiquantitative detection of mutant cfDNA with high specificity and modest sensitivity. Other more modern semiquantitative polymerase chain reaction (PCR)-based platforms, including cobas and peptide nucleic acid (PNA) PCR clamping, have been similarly evaluated in retrospective studies. 14, 15 These platforms exhibit remarkable specificity and moderate sensitivity for the detection of a limited set of point mutations and specific del mutations. For example, Mok et al. have previously reported a sensitivity of 75% and specificity of 96% for the detection of EGFR-sensitizing mutations by using a cobasbased plasma genotyping assay. These assays are thus able to rapidly detect specific EGFR mutations of interest, including L858R, specific exon 19 del alterations, and T790M with high specificity. Conversely, these platforms are limited in their ability to detect complex genomic alterations and perform multiplexed testing.
Newer platforms, including droplet digital PCR (ddPCR) and beads, emulsions, amplification and magnetics (BEAMing) PCR, utilize emulsion technology to quantify the amount of mutant cfDNA in patient plasma. Plasma genotyping assays utilizing these highly sensitive platforms have been demonstrated to rapidly detect and quantitate levels of mutant cfDNA present in the plasma of patients with metastatic NSCLC with high specificity. 7, 16 A recent study by our group utilizing a ddPCRbased platform demonstrated 100% specificity for the detection of EGFR-sensitizing and KRAS codon 12 mutations with a median turnaround time of 3 days. 7 These platforms are similarly limited by their limited ability to detect complex genomic alterations and perform multiplex testing. However, they have previously been demonstrated to be able to detect and monitor levels of common KRAS and EGFR mutations, including variable EGFR exon 19 del alterations. 17 BEAMing PCR Figure 1 . Interpretation of cell-free DNA (cfDNA) genotyping results at initial diagnosis. (A) An EGFR L858R mutation is detected in the plasma of this patient with widely metastatic disease whose tumor is shedding cfDNA and should be interpreted as a true positive result. The release of tumor DNA into the circulation is potentially associated with factors including high mitotic rate, vascularization, cell necrosis, and burden of metastatic disease. (B) No mutations are detected in the plasma of this patient whose tumor is not shedding cfDNA. In situations where tumors are not shedding cfDNA, plasma genotyping results will be unreliable and may lead to false-negative results, despite highly sensitive assays, and a biopsy for tissue genotyping should be performed.
has similarly been shown to have excellent specificity and high sensitivity for EGFR mutations in patients with advanced NSCLC. 16 Next-generation sequencing (NGS) represents a newer and more versatile platform for plasma genotyping in lung cancer. The use of NGS platforms allows for more extensive multiplexing and thus larger panels of potentially detectable genomic alterations. Many NGS platforms can also be utilized for the detection of complex genomic alterations, including rearrangements. [18] [19] [20] Copy number alterations are more difficult to detect by NGS, particularly when low-level alterations exist or overall tumor DNA content in a sample is low. 21 The turnaround time of plasma NGS assays is potentially slower than that of more focused and quantitative assays such as ddPCR. However, the capability of plasma NGS to perform multiplexed detection of a wide range of genomic alterations has led to the development of multiple commercial plasma genotyping assays utilizing NGS platforms (Guardant360 [Guardant Health, Redwood City, CA] and FoundationACT [Foundation Medicine, Cambridge, MA]). 19 
How Has Each Assay Been Validated and How Did Each Perform?
The ability of individual plasma genotyping assays to detect targetable genomic alterations can be reliably ascertained only from careful, blinded validation against a reference standard within a given tumor type, stage, and treatment time point. The rapid proliferation of plasma genotyping assays has led to confusion regarding the test characteristics and reliability of individual assays. In particular, the presumption that all plasma genotyping assays will exhibit similar test characteristics is a specious oversimplification of the varied platforms for plasma genotyping currently being utilized.
The rigor with which a given plasma genotyping assay has been validated is thus central to its utility in the rational selection of therapy for a given patient. Varying degrees of validation exist for individual plasma genotyping assays, ranging from U.S. Food and Drug Administration (FDA)-approved companion diagnostics in advanced NSCLC and those assays with prospective validations against tumor tissue genotyping to those studied primarily in constructed specimens based on cell lines, without completion of adequate clinical validation. Review of this literature can be challenging because many assays have reported their validation in abstract proceedings, without peer-reviewed publication of the details of their approach.
FDA-Approved Assay
The semiquantitative PCR-based cobas assay (Roche Molecular Systems, Pleasanton, CA) is the only FDA-approved plasma genotyping assay at present. The approval of this assay for the detection of EGFRsensitizing mutations was based on a post hoc analysis of the ENSURE study, which randomized patients with newly diagnosed EGFR-mutant metastatic NSCLC to treatment with either cisplatin-gemcitabine or erlotinib. Paired plasma and tissue was available from 517 of the 601 patients screened for this study. Both plasma and tumor tissue were tested by using the same cobas assay, which exhibited a sensitivity of 76.7% (range 70.5%-81.9%) for the detection of EGFR-sensitizing mutations and a specificity of 98.2% (range 95.4%-99.3%) with tissue genotyping used as the reference standard. 22 Although this was a post hoc analysis, the FDA granted limited approval to utilize the cobas assay in plasma for the detection of EGFR-mutant cfDNA in addition to its preexisting approval for the detection of EGFRsensitizing and T790M resistance mutations in tissue. Because of the sensitivity limitations, this plasma assay was approved as a screening test before standard tumor genotyping, and although a positive EGFR result can be acted on, a negative EGFR result should be reflexed to standard tumor genotyping.
This approval has more recently been extended to the detection of the EGFR T790M acquired resistance mutation, having been studied by using paired plasma and tissue collected in the phase I and II trials of osimertinib in EGFR-mutant NSCLC with acquired resistance to kinase inhibitors (NCT01802632 and NCT02094261). This analysis has revealed a sensitivity of 91.5% and specificity of 91.1% for the detection of EGFR T790M when compared with an orthogonal NGS plasma genotyping assay. However, discordance can be seen when comparing the plasma assay to tissue genotype as a reference standard (sensitivity 61.4%, specificity 78.6%). 23 This discordance is hypothesized to be related to the heterogeneity of drug resistance. A recent study by Oxnard et al. demonstrated that patients with T790M detected in either tumor or plasma do similarly well (62%-63% response rate, 9.7-month progressionfree survival [PFS]). 16 The small subset of patients with detectable plasma T790M but tissue negative for T790M exhibited a more modest response rate to therapy with osimertinib, which was hypothesized to be secondary to the potential for T790M to represent a minor resistance mechanism in some of these patients. Further studies will be needed to understand the clinical implications of apparent plasma false positives for T790M when this is not detected in a resistance biopsy specimen.
Prospective Validation
A limited number of plasma genotyping assays have undergone rigorous prospective validation to demonstrate their real-world test characteristics in comparison with a tissue genotyping reference standard. We recently completed a prospective study of plasma genotyping by using a ddPCR platform for the detection of EGFR and KRAS mutations in metastatic NSCLC. 7 This study specifically enrolled either patients whose cancer was newly diagnosed as well as those with acquired resistance to EGFR kinase inhibitors. This assay was demonstrated to exhibit a specificity of 100% for the detection of EGFR exon 19 del (range 91%-100%), L858R (range 85%-100%), and KRAS codon 12 mutations (range 79%-100%) in patients with newly diagnosed disease. Sensitivity was more modest, with a value of 86% (range 57%-98%) for EGFR exon 19 del, 69% (range 39%-91%) for L858R, and 64% (range 43%-82%) for KRAS. Sensitivity for the detection of EGFR T790M in patients with acquired resistance was similar at 77% (range 60%-90%), but apparent false positives for T790M were seen as with the previously mentioned studies (specificity 63% [range 38%-84%]). Interestingly, five patients in this study also had biopsy specimens characterized by multiple resistance, with discordant EGFR T790M results on tumor genotyping, thus lending credence to the theory that heterogeneity is one cause of false-positive plasma T790M results in patients with resistance. This study found increased assay sensitivity among patients with bone or liver metastases specifically, as well as an increased number of metastatic sites generally. Turnaround time in this study was 2 to 3 business days.
More recently, the ASSESS study prospectively studied genotyping for EGFR on paired plasma and tissue samples from 1162 patients with metastatic NSCLC across 56 treatment centers by using various assays according to the local practice of the individual centers. In Europe, plasma genotyping was performed in one of several central laboratories utilizing the Therascreen EGFR RGQ PCR kit (Qiagen, Valencia, CA) (49.4%), the cobas EGFR assay (34.8%), or other assays (15.8%). In Japan, plasma genotyping was performed in commercial laboratories using either PNA-locked nucleic acid PCR clamp (31.6%) or Cycleave (Takara Bio, Kusatu, Japan) (68.4%). An overall sensitivity of 46% and specificity of 97% was reported for the detection of EGFR-sensitizing mutations. The different methodologies used for plasma and tissue genotyping in this study may explain in part the lower than expected sensitivity reported in this study. 24 Two prospective studies examining NGS-based plasma genotyping by utilizing a 54-gene commercial assay (Guardant360) compared with paired tissue genotyping in advanced solid tumors, including lung tumors, have also recently been published. 19, 25 The larger of the two studies enrolled 165 consecutive patients with stage III or IV solid tumors with matched tissue genotyping samples and demonstrated a high specificity (>99.9%) and modest sensitivity (85%). 19 As previously mentioned, the use of NGS-based plasma genotyping panels allows the capability to detect complex genomic alterations, including rearrangements and potentially copy number alterations. In this analysis, a broad range of driver and resistance mutations (including ALK
Retrospective Validation
A large number of plasma genotyping assays have undergone retrospective validation by utilizing either previously collected plasma samples from large clinical trials involving metastatic NSCLC or smaller retrospective series of patients assembled from banked institutional specimens (Table 1) . 7, 16, [18] [19] [20] 22, 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] The most reliable of these studies utilized plasma samples with paired tissue genotyping collected from carefully conducted clinical trials. Mok et al. reported on a cobasbased plasma genotyping assay in 238 patients enrolled in the FASTACT-2 study of intercalated chemotherapy and erlotinib in metastatic NSCLC. 15 This study demonstrated a sensitivity of 75% and specificity of 96% for the detection of EGF-sensitizing mutations. Karachaliou et al. similarly utilized a peptide nucleic acid (PNA)-mediated PCR assay to detect EGFR-sensitizing mutations in patients enrolled in the EURTAC phase III trial of patients with metastatic EGFR-mutant NSCLC; this demonstrated a sensitivity of 78% for the detection of EGFR mutations among the 97 patients with useable plasma. 33 Wakelee et al. have reported on the use of both a commercial plasma and urine cfDNA assay on 145 samples collected from a phase I/2 study of rociletinib in patients with metastatic NSCLC with acquired resistance to EGFR kinase inhibitors. Interestingly, this study demonstrated a sensitivity of 83.4% for plasma and 82.1% for urine genotyping but a remarkable sensitivity of 96.6% when both assays were utilized in tandem. 42 Several plasma NGS assays have also reported test characteristics based on retrospective studies. Couraud et al. utilized plasma NGS performed on an IonTorrent platform (Thermo Fisher Scientific, Waltham, MA) to perform plasma genotyping on 107 never-smokers with metastatic NSCLC enrolled in the BioCAST/IFCT-1002 FDA, U.S. Food and Drug Administration; PCR, polymerase chain reaction; NGS, next-generation sequencing; DHPLC, denaturing high-performance liquid chromatography; ddPCR, digital droplet polymerase chain reaction; del, deletion; BEAMing, beads, emulsions, amplification and magnetics; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; ERBB2, erb-b2 receptor tyrosine kinase 2 gene; cfDNA, cell-free DNA; SNV, single-nucleotide variation; eTAm-Seq, enhanced tagged-amplicon sequencing; PNA, peptide nucleic acid; ARMS, amplified refractory mutation system; CAPP-Seq, cancer personalized profiling by deep sequencing.
study of tissue genotyping in lung cancer. This study demonstrated that this platform could detect singlenucleotide variants and indels with an overall sensitivity of 58% and specificity of 87%. 33 Another retrospective pilot study examining a cohort of 48 patients with metastatic NSCLC compared with tissue genotyping and orthogonal plasma ddPCR demonstrated similarly perfect specificity (100%) and more modest sensitivity (77%) by utilizing a focused NGS panel and the MiSeq platform (Illumina, San Diego, CA). 20 Multiple other retrospective studies have examined a variety of plasma genotyping platforms in a variable number of patients (see Table 1 ). Such post hoc retrospective analyses are an important step in the development of a technology, but they inherently involve study of a selected cohort of patients. Thus, such post hoc analyses may not accurately represent the diagnostic characteristics of an assay when used in practice.
In Which Patients and Clinical Situations Can This Technology Be Utilized?
Validated plasma genotyping assays exhibiting very high positive predictive value and specificity have considerable utility in treatment selection in metastatic NSCLC when an actionable genomic alteration is detected. Careful attention must be paid to the point in treatment at which this technology is utilized; current evidence from the various validation studies discussed in this article support the use of plasma genotyping in patients with newly diagnosed disease before they begin treatment and in patients with acquired resistance to treatment and clear disease progression. Importantly, patients who are currently receiving systemic therapy and responding would be expected to have reduced or altered cfDNA shed from tumors, which may cause plasma genotyping assays to yield unreliable results in this context.
The best validated clinical context in which plasma genotyping may be utilized to guide treatment selection is newly diagnosed NSCLC. Previous prospective studies of plasma genotyping assays compared against a tissue genotyping reference standard have demonstrated that specific validated assays are capable of detecting potentially actionable genomic alterations in this setting with high specificity and positive predictive value. Sensitivity in patients with newly diagnosed disease is more modest and determined by the level of tumor cfDNA shed into the peripheral circulation. The presence of increased disease burden as manifested by an increasing number of metastatic sites in general or liver and bone metastases in particular has been previously demonstrated to predict for increased sensitivity of these assays. The use of plasma genotyping for evaluating brain metastases in NSCLC is not established, but studies in primary central nervous system tumors suggest that the ability to detect tumor cfDNA in the plasma in this setting has limited sensitivity. 43 Given the high specificity of validated plasma genotyping assays in patients with newly diagnosed disease, the detection of a targetable genomic alteration should be considered sufficient evidence to initiate treatment with an appropriate targeted therapy. Individual clinical situations in which initial biopsy yielded insufficient tissue for genotyping, repeat biopsy is anatomically difficult, or an urgent need exists to identify potentially targetable genomic alterations represent contexts in which plasma genotyping may be particularly useful.
Patients with metastatic NSCLC and acquired resistance to targeted therapy manifesting as significant disease progression represent an additional population in which validated plasma genotyping assays are useful in identifying resistance mechanisms and guiding subsequent therapy. The use of plasma genotyping to detect mechanisms of drug resistance is best validated in patients with acquired resistance to EGFR kinase inhibitors. As previously discussed, ddPCR-based plasma genotyping in patients with acquired resistance to EGFR kinase inhibitors exhibits moderate sensitivity and specificity for the detection of the most common resistance mutation EGFR T790M. 44 Importantly, this study also noted that several patients that were initially noted to be T790M negative on tissue genotyping were subsequently found to be T790M positive on repeat biopsy of an alternative metastatic site presumably secondary to heterogeneity of resistance mechanisms within the same patient. Analysis of plasma genotyping performed on patients treated on a phase I trial of osimertinib in patients with acquired resistance to EGFR kinase inhibitors revealed similar overall response rates and PFS among patients who were positive for EGFR T790M on plasma genotyping as compared with tissue genotyping. 16 Similar findings have been reported in the recent confirmatory AURA3 study, which randomized metastatic NSCLC with EGFR T790M-mediated acquired resistance to either osimertinib or platinum-based chemotherapy. 45 As such, plasma genotyping may detect the presence of an acquired resistance mutation that could be missed in a tumor biopsy specimen on account of tissue heterogeneity. However, a negative plasma result should reflex to biopsy given the limited sensitivity of available assays. Additionally, the increasing recognition that second-and third-line anaplastic lymphoma kinase inhibitors are effective in a limited and not entirely congruous set of resistance mutations that emerge after initial treatment with crizotinib represents another potentially useful niche for plasma genotyping in acquired resistance. [46] [47] [48] [49] How Should the Results of Plasma Genotyping Be Interpreted and Used for Decision Making?
Once the decision to utilize plasma genotyping in an appropriate clinical context has been made, practitioners can quickly find themselves struggling to interpret the outcome of the assay. Although single-gene cfDNA analysis with a targeted panel is feasible when the gene of interest is known, such as in the case of EGFR-sensitizing or resistance mutations in NSCLC, most commercially available plasma genotyping assays utilize an NGS platform to detect alterations in a large panel of genes. Although these larger assays may be useful when the specific mechanism of interest is unknown, only a fraction of the genes identified in such panels represent potentially targetable driver alterations. The interpretation of plasma genotyping assays thus hinges on careful consideration of the concepts of tumor shed and detection of a driver mutation.
The detection of mutant cfDNA in a plasma genotyping assay suggests that the tumor under consideration is shedding cfDNA. Although the detection of any mutant cfDNA may imply that shed is occurring, the detection of a driver genomic alteration is the strongest indicator of cfDNA shed, given the ubiquitous expression of such alterations in a specific patient's tumor. The detection of such a driver alteration may be used to both infer tumor cfDNA shed and exclude the presence of other potential drivers. For example, the detection of a KRAS codon 12 mutation in a patient with metastatic NSCLC may be used to exclude the presence of an EGFR or ALK alteration, given that these have been well described as not overlapping. 50 In situations where a driver mutation is not detected, one cannot know whether this is because of nominal tumor shed and a false-negative assay result versus adequate tumor shed and true negative genotyping result (see Fig. 1 ). Thus, in the absence of a positive plasma genotyping result, tumor tissue genotyping should be used to guide care. Plasma genotyping performed at initial diagnosis or at the time of disease progression should thus be considered highly actionable when a targetable genomic alteration or a nontargetable driver mutation is detected. In the case of a targetable alteration, treatment with an appropriate targeted therapy can be initiated given the high positive predictive value of plasma genotyping assays without the need for confirmatory tissue genotyping.
Similar principles may be applied to the interpretation of plasma genotyping in cases of acquired resistance to kinase inhibitors in metastatic NSCLC. In this context, the detection of the patient's known initial driver mutation should serve as the primary arbiter of whether the patient's tumor is shedding cfDNA. If the original driver mutation can be detected, then the presence of an actionable resistance mutation or its absence can be considered reliable and actionable. For example, in a patient with acquired resistance to an EGFR kinase inhibitor, detection of the patient's original EGFRsensitizing mutation with the added presence of a T790M mutation can be considered actionable; if T790M is not detected in plasma, there is still a chance of a subclonal T790M that could be detected on biopsy. Furthermore, tissue genotyping would be helpful in the latter situation to identify potential resistance mechanisms not easily identified by plasma genotyping, such as small cell transformation or MET amplification. Similarly, plasma genotyping that does not detect the original targetable driver mutation should be considered a wholly unreliable false-negative result, which should prompt repeat biopsy for tissue genotyping (Fig. 2) .
Mutant allele fraction, or the proportion of mutant DNA fragments at a given locus, should also be carefully considered in the interpretation of plasma genotyping results. Although the cobas assay and scorpion-ARMS platforms are semiquantitative in nature, ddPCR, BEAMing PCR, and NGS platforms have the capability to accurately quantify mutant allele fractions. Mutant allele fraction can be influenced by factors including tumor physiology related to cfDNA shed, as well as by analytic factors of the particular assay used. Quantitative assays generally have the capability of detecting cfDNA present at an allele fraction of less than 1% as its lower limit. It is important to note that mutations that are positive at low levels could potentially represent false positives if an assay has been inadequately validated and should be interpreted with caution. Variants found near the limit of detection (<1% allelic fraction) risk being due to assay artifact and should be interpreted with caution, especially when using an assay that has not been FDA approved.
What Are the Future Directions of This Technology?
Plasma genotyping now has a clearly established role in newly diagnosed metastatic NSCLC, as well as in acquired resistance to kinase inhibitors. This technology is eminently actionable given its high specificity but is limited by moderate sensitivity. Strategies that offer the potential to increase sensitivity, such as utilizing orthogonal urine cfDNA assays or incorporating analysis of exosomes, are particularly promising. 42, 51 However, the versatility of this technology extends beyond these initial practical uses and encompasses potential utility in real-time monitoring of response to therapy. The potential use of this technology to monitor treatment response was recently evaluated by Mok et al. by using plasma samples collected from patients treated on the FASTACT-2 study of chemotherapy with or without intercalated erlotinib for advanced NSCLC. In an exploratory analysis of patients with detectable EGFRmutant cfDNA at baseline using the cobas assay, those with undetectable mutant cfDNA after two cycles of therapy exhibited a median PFS of 12 months compared with 7.2 months (hazard ratio ¼ 0.32, p < 0.0001) for those patients with residual detectable mutant cfDNA. 15 These findings underscore the potential to utilize quantitative tumor cfDNA monitoring strategies to identify patients with suboptimal responses to therapy. Whether utilizing alternative treatment strategies in these patients can improve patient outcomes is a key question for future research studies. Furthermore, this technology exhibits significant potential to monitor the genetic evolution of tumors, allow early detection of acquired resistance mechanisms for the purpose of early treatment modification, identify patients with earlier-stage NSCLC who are at high risk for relapse and may benefit from additional adjuvant treatment, and serve as a tool to rapidly identify novel mechanisms of resistance to promising new therapies in clinical development. Validating the role of plasma genotyping for these diverse applications will require well-planned clinical studies as well as an improved understanding of the halflife and kinetics of cfDNA in response to various forms of systemic therapies.
